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We read with interest the article by Ferrari and col-
leagues showing in a small prospective study of chronic
obstructive pulmonary disease (COPD) patients that
interleukin-6 (IL-6) is a useful biomarker predicting
worsening exercise tolerance and greater mortality [1].
We outline below the significance of this finding and its
potential impact on the future management of COPD.
The findings by Ferrari and colleagues concur with
other prospective studies, including the recently pub-
lished ECLIPSE study, showing elevated IL-6 is a clinic-
ally useful marker predicting poor outcomes in COPD
[2-4]. In large prospective studies a similar utility was
found for elevated C-reactive protein (CRP), whose ex-
pression is controlled primarily by IL-6 and also associ-
ated with poor outcomes in COPD [5-7]. These poor
outcomes include poorer exercise tolerance, worsening
lung function, greater exacerbation rate, greater co-
morbidities (lung cancer, pneumonia, diabetes and cor-
onary artery disease) and most importantly, greater
mortality. Collectively, these findings suggest that the
natural history of COPD and its prognosis can be pre-
dicted to some extent by elevated IL-6, a serum marker
of systemic inflammation. These observations also suggest
that systemic inflammation plays a primary pathogenic
role in the natural history of this disease (“reverse” effect,
Figure 1), not just a secondary phenomenon from pul-
monary inflammation (the “spill over” effect, Figure 1) [8].
In animal models where IL-6 is over-expressed, the clin-
ical phenotype closely resembles that of COPD further
suggesting a primary role for IL-6 (and systemic inflam-
mation) in the development of COPD [9], We have re-
cently reviewed the literature and suggest that IL-6
-mediated systemic inflammation is also relevant to many
of the COPD-related co-morbidities described above [8].
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distribution, and reproduction in any mediumfurther data to suggest that elevated IL-6 plays an active
role in the progression of this important disease [1].
If these observations are true, then it follows that
HMGCoA reductase inhibitors (statins) might be benefical
in COPD patients through their powerful inhibition of IL-
6-mediated systemic inflammation [8]. Indeed, there is a
large body of data from numerous observational studies
showing that statin therapy reduces both morbidity and
mortality in COPD including; reducing the rate of infect-
ive exacerbations, slowing the decline in FEV1, reducing
mortality from pneumonia or infective exacerbations
and improving exercise tolerance [8]. This last clinical
feature of COPD is very important as it significantly af-
fects quality of life. In the first randomized control trial
of statin therapy in COPD, exercise tolerance was im-
proved by nearly 50% after 6 months of statin therapy
compared to placebo [10]. This improvement correlated
with a significant reduction in serum IL-6 level (and
CRP) but not lung function [10], suggesting IL-6-medi-
ated systemic inflammation might be one of the primary
determinants of poor exercise tolerance. Also of consid-
erable importance, is the recent finding that elevated
IL-6 or CRP levels are associated with increased risk of
lung cancer [11], particularly in patients with COPD
[12], and that lung cancer mortality is reduced by 17%
with statin use [Supplementary Figure S11 from ref.
[13]. Together with the findings of the observational
studies described above, these results make a strong
argument for examining the role of statins as adjunct
therapy to inhaler therapy in COPD (Figure 1) [8,14].
This is particularly the case as current inhaler therapy
in COPD is symptom-based, minimizing breathlessness
and reducing exacerbations, while statin-based systemic
therapy, inhibiting both systemic and pulmonary in-
flammation, appears to confer significant disease modi-
fying benefits. It also argues in favor of investigating the
utility of measuring serum IL-6 (or it’s surrogate CRP)
in patients with COPD to target and monitor therapy
[1-7,14].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Proposed relationship between Interleukin-6 mediated systemic inflammation, pulmonary inflammation, COPD and
COPD co-morbidities.
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http://respiratory-research.com/content/14/1/74We conclude that the study of Ferrari and colleagues
confirms earlier studies showing that outcomes in
COPD are related to IL-6-mediated systemic inflamma-
tion [1]. This observation not only provides the basis on
which to better phenotype patients with COPD [14], but
more importantly highlights the important potential
utility of statin therapy as a significant disease-modifying
therapy in COPD [8]. This hypothesis requires urgent
examination in clinical trials.
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